Top Page
Microba Life Sciences Limited
(Sydney:MAP)
Microba Life Sciences Limited (MAP) vs. iShares MSCI Australia ETF (EWA)
Microba Life Sciences Limited Business Overview & Revenue Model
Microba Life Sciences Limited Financial Statement Overview
| Breakdown | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 12.09M | 5.42M | 4.69M | 3.73M | 2.91M |
| Gross Profit | 5.91M | -6.77M | 2.37M | -5.30M | -4.05M |
| EBITDA | -17.10M | -17.07M | -9.86M | -6.28M | -5.53M |
| Net Income | -19.94M | -12.68M | -11.47M | -7.52M | -6.65M |
Balance Sheet | |||||
| Total Assets | 58.04M | 46.95M | 39.48M | 18.49M | 10.81M |
| Cash, Cash Equivalents and Short-Term Investments | 20.89M | 32.04M | 30.58M | 13.03M | 6.90M |
| Total Debt | 1.58M | 1.14M | 1.33M | 269.02K | 563.65K |
| Total Liabilities | 16.82M | 8.23M | 5.94M | 3.46M | 3.10M |
| Stockholders Equity | 41.22M | 38.57M | 33.54M | 14.94M | 7.70M |
Cash Flow | |||||
| Free Cash Flow | -19.95M | -15.43M | -12.32M | -7.85M | -5.18M |
| Operating Cash Flow | -15.57M | -12.39M | -10.45M | -7.18M | -4.32M |
| Investing Cash Flow | -13.95M | -3.00M | -1.73M | -522.48K | -856.17K |
| Financing Cash Flow | 18.39M | 16.68M | 29.22M | 13.84M | 1.08M |
Microba Life Sciences Limited Technical Analysis
Microba Life Sciences Limited Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
73 Outperform | AU$36.61M | 20.00 | 87.09% | 9.33% | 1.86% | 16.10% | |
65 Neutral | ¥354.70B | 11.38 | -2.99% | 2.49% | 11.76% | -10.21% | |
52 Neutral | AU$53.89M | ― | -51.49% | ― | 80.84% | 57.59% | |
45 Neutral | AU$24.52M | ― | -104.23% | ― | ― | -17.26% | |
45 Neutral | AU$78.36M | ― | -47.52% | ― | 44.61% | 16.40% | |
45 Neutral | AU$41.30M | ― | -39.07% | ― | 26.07% | 0.85% | |
38 Underperform | AU$49.44M | ― | -33.42% | ― | 158.37% | 36.73% |
Microba Life Sciences Limited Corporate Events
Microba Life Sciences Limited has announced its Q4 FY25 Investor Presentation and Webinar, which will be presented by CEO Dr. Luke Reid. The company invites investors and interested parties to engage with management and submit questions ahead of the webinar. This initiative aims to enhance communication with stakeholders and keep them informed about the company’s developments and strategic direction.
The most recent analyst rating on (AU:MAP) stock is a Buy with a A$0.33 price target. To see the full list of analyst forecasts on Microba Life Sciences Limited stock, see the AU:MAP Stock Forecast page.
Microba Life Sciences Limited reported significant growth in its core testing products, with record sales of MetaXplore and increasing adoption of MetaPanel in both Australia and the UK. The company achieved a 30% increase in FY25 revenue, driven by strategic focus on high-value products and a successful capital raise, positioning it for sustained growth and market expansion.
The most recent analyst rating on (AU:MAP) stock is a Buy with a A$0.33 price target. To see the full list of analyst forecasts on Microba Life Sciences Limited stock, see the AU:MAP Stock Forecast page.
Microba Life Sciences Limited has announced the release of its Q4 FY25 Quarterly Activities Report, Appendix 4C, and a Quarterly Investor Presentation scheduled for 22 July 2025. The company will also host a Quarterly Investor Webinar on 23 July 2025, led by CEO Dr. Luke Reid, to engage with investors and discuss the latest developments. This initiative reflects Microba’s commitment to transparency and stakeholder engagement, potentially enhancing its industry positioning and investor relations.
The most recent analyst rating on (AU:MAP) stock is a Buy with a A$0.33 price target. To see the full list of analyst forecasts on Microba Life Sciences Limited stock, see the AU:MAP Stock Forecast page.
Microba Life Sciences Limited has announced a general meeting scheduled for August 8, 2025, to seek shareholder approval for several capital initiatives. These initiatives include a $2.0 million underwritten Share Purchase Plan (SPP) and a $12.5 million placement to expand the adoption of their core microbiome testing products, MetaXplore and MetaPanel, in Australia and the UK. The capital raise aims to support the company’s growth phase, strengthen its working capital, and drive long-term value creation for stakeholders. The meeting will also address the company’s commercial collaboration with Sonic Healthcare, its largest shareholder.
The most recent analyst rating on (AU:MAP) stock is a Buy with a A$0.33 price target. To see the full list of analyst forecasts on Microba Life Sciences Limited stock, see the AU:MAP Stock Forecast page.
Mercer Investments (Australia) Limited, as the responsible entity of the Mercer Australian Small Companies Fund, has ceased to be a substantial holder in Microba Life Sciences Limited as of June 27, 2025. This change follows an increase in the total shares on issue by 67,177,796 shares, impacting the fund’s voting interests in the company.
The most recent analyst rating on (AU:MAP) stock is a Buy with a A$0.26 price target. To see the full list of analyst forecasts on Microba Life Sciences Limited stock, see the AU:MAP Stock Forecast page.
Microba Life Sciences Limited has announced a capital raise through a placement and a share purchase plan, aiming to gather a total of $14.5 million before costs. This financial maneuver involves issuing new ordinary shares and options, with the first tranche of shares already issued and quoted on the ASX. This capital raise is expected to bolster Microba’s financial position, potentially enhancing its market presence and operational capabilities.
The most recent analyst rating on (AU:MAP) stock is a Buy with a A$0.33 price target. To see the full list of analyst forecasts on Microba Life Sciences Limited stock, see the AU:MAP Stock Forecast page.
Microba Life Sciences Limited has announced a Securities Purchase Plan (SPP) offering eligible shareholders the opportunity to subscribe for new shares and options. The SPP aims to raise up to $2 million and is fully underwritten by Morgans Corporate Limited and Canaccord Genuity (Australia) Limited. The issuance of new shares and options is contingent upon shareholder approval at a general meeting scheduled for August 8, 2025. This move is part of Microba’s strategy to strengthen its financial position and expand its market presence.
The most recent analyst rating on (AU:MAP) stock is a Buy with a A$0.33 price target. To see the full list of analyst forecasts on Microba Life Sciences Limited stock, see the AU:MAP Stock Forecast page.
Microba Life Sciences Limited has announced the quotation of 67,177,796 fully paid ordinary securities on the Australian Securities Exchange (ASX) under the code MAP. This move is part of previously announced transactions and is expected to enhance the company’s market presence and liquidity, potentially benefiting stakeholders by increasing the accessibility of its shares.
The most recent analyst rating on (AU:MAP) stock is a Buy with a A$0.33 price target. To see the full list of analyst forecasts on Microba Life Sciences Limited stock, see the AU:MAP Stock Forecast page.
Microba Life Sciences Limited, listed on the ASX under the ticker MAP, has announced the lifting of its trading suspension following a capital raising announcement. This development is expected to have a positive impact on the company’s operations, potentially enhancing its market positioning and offering new opportunities for stakeholders.
The most recent analyst rating on (AU:MAP) stock is a Buy with a A$0.33 price target. To see the full list of analyst forecasts on Microba Life Sciences Limited stock, see the AU:MAP Stock Forecast page.
Microba Life Sciences Limited has announced a proposed issue of securities under a securities purchase plan, with the offer set to close on August 6, 2025, and the issue date on August 13, 2025. This move is part of the company’s strategic efforts to raise capital, potentially impacting its market positioning and providing opportunities for stakeholders to invest in its future growth.
The most recent analyst rating on (AU:MAP) stock is a Buy with a A$0.33 price target. To see the full list of analyst forecasts on Microba Life Sciences Limited stock, see the AU:MAP Stock Forecast page.
Microba Life Sciences Limited has announced a proposed issue of securities, specifically options expiring on January 13, 2027, with a total of 46,222,222 securities to be issued. This strategic move is expected to bolster the company’s financial position and potentially enhance its market presence, offering stakeholders a glimpse into the company’s growth plans.
The most recent analyst rating on (AU:MAP) stock is a Buy with a A$0.33 price target. To see the full list of analyst forecasts on Microba Life Sciences Limited stock, see the AU:MAP Stock Forecast page.
Microba Life Sciences Limited announced a proposed issue of securities, including options expiring in August 2027 and ordinary fully paid shares. This move is part of the company’s strategy to raise capital, potentially enhancing its market position and operational capabilities in the life sciences sector.
The most recent analyst rating on (AU:MAP) stock is a Buy with a A$0.33 price target. To see the full list of analyst forecasts on Microba Life Sciences Limited stock, see the AU:MAP Stock Forecast page.
Microba Life Sciences Limited has announced a proposed issue of 67,177,796 fully paid ordinary securities, with the issuance date set for June 27, 2025. This move is part of a strategic effort to enhance its capital structure, potentially impacting its market position and offering new opportunities for stakeholders.
The most recent analyst rating on (AU:MAP) stock is a Buy with a A$0.33 price target. To see the full list of analyst forecasts on Microba Life Sciences Limited stock, see the AU:MAP Stock Forecast page.
Microba Life Sciences Limited has successfully raised $14.5 million through a two-tranche placement and a share purchase plan to expand the clinical adoption of its microbiome testing products. The funding, supported by major shareholder Sonic Healthcare Limited, will be used to enhance product development, sales, and marketing efforts in Australia and the UK. Additionally, Microba has signed an exclusive agreement with The Doctors Laboratory in the UK, which is expected to strengthen its market presence and drive growth. The company aims to achieve regional break-even points by the end of FY26 and is on a strategic path to reach group breakeven within three years.
The most recent analyst rating on (AU:MAP) stock is a Buy with a A$0.33 price target. To see the full list of analyst forecasts on Microba Life Sciences Limited stock, see the AU:MAP Stock Forecast page.
Microba Life Sciences Limited has requested a voluntary suspension of its securities from the ASX as it prepares to announce a capital raise. The suspension, effective from June 23, 2025, is expected to last until the company is ready to release details of the capital raise, anticipated by June 24, 2025. This move is part of Microba’s strategic efforts to secure funding for its ongoing projects in microbiome diagnostics and therapeutics, potentially impacting its market positioning and stakeholder interests.
The most recent analyst rating on (AU:MAP) stock is a Buy with a A$0.33 price target. To see the full list of analyst forecasts on Microba Life Sciences Limited stock, see the AU:MAP Stock Forecast page.
Microba Life Sciences Limited has requested a trading halt on its shares pending an announcement regarding a proposed capital raise. This strategic move is intended to facilitate the capital raise process, which could have significant implications for the company’s financial strategy and market operations.
The most recent analyst rating on (AU:MAP) stock is a Buy with a A$0.33 price target. To see the full list of analyst forecasts on Microba Life Sciences Limited stock, see the AU:MAP Stock Forecast page.
Microba Life Sciences Limited announced breakthrough results from their MetaPanel™ Pathogen Study, highlighting the test’s ability to identify clinically significant pathogens in patients with chronic gastrointestinal symptoms. The study found that 20% of patients tested positive for pathogens, with 78.4% of these pathogens often missed by routine tests. Notably, 100% of patients treated based on MetaPanel results experienced complete symptom resolution, underscoring the test’s potential to transform gastrointestinal diagnostics and treatment. This advancement positions Microba as a leader in precision gastroenterology, offering a novel pathway for diagnosing and treating chronic GI conditions.
The most recent analyst rating on (AU:MAP) stock is a Buy with a A$0.33 price target. To see the full list of analyst forecasts on Microba Life Sciences Limited stock, see the AU:MAP Stock Forecast page.
Microba Life Sciences Limited has announced preliminary results from a study involving over 4,600 patients using its MetaXplore™ GI Plus test. The study found that 71.4% of the reports identified actionable results, with a significant portion showing abnormal microbiome markers linked to gastrointestinal health. The findings suggest that the MetaXplore test can significantly aid clinicians in diagnosing and managing chronic lower gastrointestinal disorders. Additionally, a separate survey indicated that 65.5% of patients reported health improvements after following clinician-directed recommendations based on the test results. This highlights the potential of MetaXplore to reshape clinical management and improve outcomes for patients with these conditions, addressing an estimated addressable market of over 82 million patients across several countries.
The most recent analyst rating on (AU:MAP) stock is a Buy with a A$0.33 price target. To see the full list of analyst forecasts on Microba Life Sciences Limited stock, see the AU:MAP Stock Forecast page.
Microba Life Sciences Limited announced the cessation of 1,200,000 securities due to the expiry of options without exercise or conversion as of April 29, 2025. This development may impact the company’s capital structure and could influence investor perceptions regarding the company’s financial strategies and market positioning.
Microba Life Sciences Limited has released its Q3 FY25 Investor Presentation and Webinar, presented by CEO Dr. Luke Reid. The presentation is available on demand via Microba’s Investor Hub, and stakeholders are encouraged to engage by submitting questions through the platform. This initiative reflects Microba’s commitment to transparency and stakeholder engagement, potentially enhancing its industry positioning by fostering investor confidence.
Microba Life Sciences Limited reported significant growth in its testing products for Q3 FY25, with MetaXplore and MetaPanel showing strong sales in Australia and the UK. The company’s strategic focus on core diagnostic products is reflected in its financial performance, with expected revenue growth and a transition to a partnering-focused phase for its therapeutics business. The successful clinical studies on MetaPanel for Inflammatory Bowel Disease (IBD) highlight its potential to transform patient care by detecting pathogens missed by routine testing, supporting its integration into standard care protocols.
Microba Life Sciences Limited announced the release of its Q3 FY25 Quarterly Activities Report and Investor Presentation, scheduled for April 30, 2025. The company will also provide a video presentation by CEO Dr. Luke Reid, accessible through its Investor Hub, allowing stakeholders to engage and submit questions. This initiative underscores Microba’s commitment to transparency and stakeholder engagement, potentially enhancing its market position and investor relations.